Fundamental analysis · SEC EDGAR · TTM through 30/09/2026
BIIB · Nasdaq · Healthcare
Fundamental quality
37
out of 100
Biogen Inc. earns a fundamental-quality score of 37 out of 100, profiling it as a company with demanding fundamentals. Its score rests mainly on its financial strength (net debt 3.67× EBITDA). Its weakest area is its growth (revenue -4.5%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Biogen is one of the veteran biotechs, specialized in nervous-system diseases: multiple sclerosis, spinal muscular atrophy and the riskiest bet of all, Alzheimer's. It lives the classic pharma dilemma: mature franchises in decline and a new generation that needs to work.
EPS growth: -33.8% · Revenue growth: -4.5%
Net margin: 3.4% · ROE: 1.8% · ROIC: 2.4%
Net debt/EBITDA: 3.67x · FCF: 20.1%
Source: SEC EDGAR · TTM through 30/09/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 13,445 | 4,001 | 3,805 | 6,095 |
| 2021 | 10,982 | 1,556 | 3,382 | 5,012 |
| 2022 | 10,173 | 3,047 | 1,144 | 2,862 |
| 2023 | 9,836 | 1,161 | 1,270 | 5,888 |
| 2024 | 9,676 | 1,632 | 2,722 | 3,921 |
| 2025 | 9,891 | 1,293 | 2,051 | 3,278 |
Between 2020 and 2025, revenue went from $13,445M to $9,891M (-26%) and net income went from $4,001M to $1,293M (-68%). Meanwhile, its margins have narrowed (from 30% to 13%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the nine months ended September 30, 2026, versus the nine months ended September 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Biogen Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Biogen Inc. a good company to invest in?
In terms of business quality, Biogen Inc. scores 37 out of 100 in our analysis, placing it as a company with demanding fundamentals. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Biogen Inc. a profitable company?
Biogen Inc. is profitable, with a net margin of 3.4%, though a thin one.
Does Biogen Inc. have a lot of debt?
Yes, its leverage is high: net debt is 3.67 times its EBITDA.
Is Biogen Inc. growing?
Its revenue has fallen 4.5% annualized in recent years.
Does Biogen Inc. generate cash?
Yes. It converts about 20.1% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Molina Healthcare (MOH) · Medline (MDLN) · Tenet Healthcare (THC) · Universal Health Services (UHS) · Teva Pharmaceutical Industries (TEVA) · Davita (DVA) · see more →
Who's behind the methodology and model · how the score is computed
Data: see Biogen Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.